echocardiography (stress echo), exercise stress nuclear scintigraphy (stress nuclear), or exercise treadmill test (ETT) study. The model was developed to evaluate the potential cost savings of coronary CTA vs. cardiac catheterization in patients who have an abnormal or non-diagnostic test result. RESULTS: A strategy utilizing coronary CTA to evaluate patients with an abnormal or non-diagnostic stress echo, stress nuclear, or ETT study was cost-saving compared with a conventional strategy of cardiac catheterization for these patients, up to a CAD prevalence rate within the study population of Յ33-72%, depending on the costs assumptions used in the model. CONCLUSIONS: An evaluation strategy that uses coronary CTA for the primary evaluation of patients with abnormal ETT, stress echo, or stress nuclear test may reduce costs in a patient population with a low to intermediate prevalence of CAD. OBJECTIVES: Acute heart failure (AHF) is life a threatening disease which includes variable causes and complications. The aim was to assess clinical characteristics, medication and costs during hospitalization in patients with AHF. METHODS: Patients hospitalized in a cardiological dpt. of the Faculty Hospital Brno in January 2005-July2007 were classified according to the Guidelines on the diagnosis and treatment of AHF by the European Society of Cardiology and their medication was followed at admission and during the stay. In-patient care costs include flat rate of admission, stay and medicinal procedures. (1€ = 25 CZK) RESULTS: In total, 1213 patients (57.5% male, mean age 72.5 years) with AHF were analyzed. The chronic medication involved diuretics in 51%, less than half used antiplatelet drugs, beta-blockers and ACE-I; statins (28.3%), nitrates (23.6%), digoxin (21.8%). Positive inotropics were indicated in acute state: norepinephrine (20.4%), dopamine (11.4%), dobutamine (10%), epinephrine (9.5%) and levosimendan (4.8%). New-onset AHF (57%) was more common than decompensated AHF and was concerned with higher costs. AHF with mild signs and symptoms prevailed (49.3%), pulmonary oedema and cardiogenic shock were both in 13%. Total direct in-hospital expenses were €4.4 million; mean in-patient cost was €3621. The most expensive were patients in cardiogenic shock with only 3 days of hospitalization (overall mean length-of-stay 8.2 days). The predictors of high costs were antiarrhythmic interventions (PM and ICD; 5.9% patients) making up to 21% of total expenses and revascularizations (coronary angiography followed by PCI in 31.5% patients) which made 41% of total expenses. CONCLUSIONS: The treatment of heart failure patients uses 1-2% of health care budget in developed European countries of which 2/3 are being spent on hospitalizations. AHF hospitalization is more frequent as the population ages (62% patients were more than 70 years old) and is associated with poor prognosis (in-hospital mortality 14.5%).
(DES). METHODS: We identified all patients undergoing PCI from 2000 -2002 and from 2004 -April 31, 2006 in a large PCI registry that includes demographic, clinical, angiographic, procedural and outcome information. Administrative data were used to estimate length of stay (LOS) and procedural costs, as well as cardiac hospitalization costs during year follow-up. We used logistic and Cox proportional hazard models to estimate the adjusted risk of adverse events within propensity score stratum and generalized linear modeling to predict LOS, procedural and follow-up hospitalization costs by treatment era. RESULTS: We compared 3422 patients from the DES era (mean age 67, 69% male) and 4303 patients from the pre-DES era (mean age 67, 70% male). 90% of pre-DES era patients had bare-metal stents implanted; whereas 83% of DES era patients had DES. Adverse event rates were similar between time periods (adjusted odds ratio for in-hospital myocardial infarction (MI) in DES era: 0.79; 95% CI 0.62, 1.00). During a median 22 month follow-up, the adjusted incidence of death or MI was similar between cohorts, but follow up procedures were reduced in the DES era (hazard ratio for target lesion revascularization in DES era vs. pre-DES era: 0.58; 95% CI 0.50, 0.68). Models predict a mean LOS reduction of 0.40 days in the DES era and procedural cost savings of $2053 (95% bootstrapped CI of adjusted mean difference: -2937, -1197). Follow-up cardiac hospitalization costs were similar. CONCLUSIONS: In a large unselected PCI cohort, the introduction of DES was associated with improved clinical outcomes during follow-up and reduced in-hospital costs. These data suggest costly new technologies can be introduced into a general practice setting while maintaining and improving patient outcomes at an incremental cost savings.
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COST-EFFECTVENESS OF ENDOVASCULAR ANEURYSM REPAIR VERSUS OPEN SURGICAL REPAIR: NON-RUPTURED INFRARENAL ABDOMINAL AORTIC ANEURYSM IN AN ELECTIVE SETTING
Hayes P 1 , Ryan J 2 , Jensen M 2 , Harrison L 2 , Wyatt M 3 , Bradbury A 4 , Brasseur P 5 1 Addenbrooke's Hospital, Cambridge, UK, 2 Abacus International, Bicester, UK, 3 Freeman Hospital, Newcastle upon Tyne, UK, 4 University of Birmingham, Birmingham, UK, 5 Medtronic Europe Sàrl, Tolochenaz, Switzerland OBJECTIVES: To determine the cost-effectiveness of endovascular aneurysm repair (EVAR) versus open surgical repair (OSR) for non-ruptured, infrarenal abdominal aortic aneurysm (AAA) in an elective setting. The analysis was conducted for the recent appraisal of EVAR by the National Institute for Health and Clinical Excellence in England and Wales. METHODS: A twostage cost-utility model was developed from an NHS perspective to capture the lifetime costs and health outcomes of EVAR. The model population represented a 70-year old, fit for open surgery, with an AAA at least 5.5 cm in diameter. A decision-tree model captured the short-term costs and health outcomes of patients during the first 30-days post-repair, followed by a Markov model, with monthly cycles during the first 24 months and yearly cycles thereafter, until death. Clinical endpoints included mortality and complications. Primary data were derived from the EVAR I randomised controlled trial where reported. To reflect current clinical practice other sources including retrospective patient data were used. Costs were applied from trial data and national reference sources. A discount rate of 3.5% was applied to costs and health outcomes. Univariate and multivariate sensitivity analyses were performed for all parameters. An incremental costeffectiveness ratio (ICER) reflecting incremental lifetime costs per quality adjusted life year (QALY) gained was calculated for the base-case analysis. RESULTS: Base case analysis, resulted in an ICER of £15,681 per QALY for EVAR versus OSR. The average QALY gain at 30 years post surgery was 0.072 for EVAR compared with OSR. Results were most sensitive to the relative risk of short-term mortality, cost of the EVAR device and long-term rate of secondary interventions in the EVAR group. CONCLU-SIONS: The results suggest that EVAR is cost-effective for nonruptured AAA versus OSR with a probability of 66% and 60% based on willingness-to-pay thresholds of £30,000 and £20,000, respectively.
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COST-EFFECTIVENESS OF CLOPIDOGREL IN COMBINATION WITH ASPIRIN FOR ACUTE CORONARY SYNDROMES IN AUSTRALIA
Liew D 1 , Cordony A 2 1 The University of Melbourne, Melbourne, Victoria, Australia, 2 Sanofi-Aventis Australia, Macquarie Park, NSW, Australia OBJECTIVES: To determine if clopidogrel plus aspirin is costeffective compared to aspirin alone for patients following ACS, from the Australian health care perspective. METHODS: A Markov model was constructed by extrapolation of data from the Australian Acute Coronary Syndromes Prospective Audit (ACACIA) registry (n = 2553) in the first model cycle, and the Reduction in Atherothrombosis for Continued Health (REACH) registry (n = 2567 Australian patients) in subsequent cycles. Decision analysis was applied to compare clopidogrel plus aspirin against aspirin alone. Efficacy data were drawn from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial. A utility study was conducted in 2007 with 86 participants using health states validated by clinical experts. Drug and disease costs were obtained from literature and health care reimbursement fees, and updated using Australian health price indices. An annual discount rate of 5% was applied to all costs and effects beyond one year in accordance with reimbursement guidelines. Twenty sensitivity analyses were undertaken, varying the 95% confidence intervals surrounding efficacy measures from CURE, uncertainty in cost and utility inputs and variations to time horizons and discount rates. RESULTS: The base-case incremental cost-effectiveness ratio (ICER) with a ten-year time horizon was A$14,496/QALY and remained below the unofficial cost-effective threshold of $A40,000/QALY throughout all sensitivity analyses. Treatment remained cost-effective up to an inflated clopidogrel cost of 229%, and even when acute hospitalization costs were removed (A$20,267/QALY). The five-year ICER was A$20,124/QALY. Sensitivity analyses demonstrated that the ICER ranged from A$6443/QALY when the risk of events observed in ACACIA were applied to all years, up to A$36,974/QALY using the 95% upper confidence interval for efficacy. CONCLUSIONS: Clopidogrel with aspirin represents a highly cost-effective treatment option for patients with ACS in Australia. This was confirmed by the Australian reimbursement authority's recent recommendation that treatment with clopidogrel plus aspirin be reimbursed for ACS patients.
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COST-UTILITY ANALYSIS IN PATIENTS WITH DRUG REFRACTORY CONCOMITANT ATRIAL FIBRILLATION IN SPAIN
López Gude MJ 1 , Rodríguez Bezos D 2 , Rodríguez Barrios JM 2 , Serrano Contreras D 2 1 Hospital 12 Octubre, Madrid, Spain, 2 Medtronic Iberia, Madrid, Spain OBJECTIVES: Atrial fibrillation is the most common arrhythmia in the clinical practice. It is related with an important morbidity, a decrease in patients' quality of life and is a risk factor of suffering a stroke. The Spanish estimated atrial fibrillation prevalence is 2.52%, and is higher over 60 years. Radiofrequency surgical ablation is a treatment alternative to restore sinus rhythm in drug-refractory atrial fibrillation patients. The main objective of this study is to develop a five-year cost-utility analysis including the different treatment alternatives in drugrefractory concomitant atrial fibrillation patients in the Spanish setting. METHODS: A Markov model was developed to simulate the evolution of a 1000 cohort of over 40 years old patients with paroxistical and persistent atrial fibrillation that could be treated with: non ablation, surgical ablation and catheter ablation. The model included four heath states: sinus rhythm, atrial fibrillation, dependent stroke and death. The time horizon was five years, with a cycle length of three months. The data of cost and effects were obtained from the published literature and experts opinion. Costs and effects were discounted at 3.5%. A sensibility analysis was developed to determine the robustness of the main variables of the model. RESULTS: Based on 1000 patients simulation with concomitant atrial fibrillation, preliminary results show that the QALY gained were 3.79, 4.25, and 4.23, respectively for no ablation, surgical ablation and catheter ablation. The costs per patient were respectively 8889, 11,157 and 11,865 . The cost per QALY gained of the most effectiveness option (surgical ablation) when compared with no ablation is €4909. Surgical ablation is a dominant option vs. catheter ablation. CONCLUSIONS: These preliminary results show that surgical ablation is a cost-effective treatment option in drug refractory concomitant atrial fibrillation patients in the Spanish setting, with less cost and a higher efficacy than the catheter ablation.
PCV72 COST/UTILITY ANALYSIS (CUA) OF VALSARTAN FOR THE TREATMENT OF CONGESTIVE HEART FAILURE (CHF) IN ITALY BASED ON THE VAL-HEFT TRIAL
Pradelli L, Iannazzo S, Zaniolo O AdRes Srl, Turin, Italy OBJECTIVES: CUA of the use of valsartan when added to standard treatment in CHF management in Italy. METHODS: A probabilistic Markov model, made up of states corresponding to NYHA classes II, III, IV, and death, was developed in WinBUGS to apply findings from the Val-HeFT Trial to the Italian setting. Simulation lasts 10 years, divided in 1-month cycles. Transition probabilities represent individual mortality, derived from the general population mortality by gender and age multiplied by a NYHA state-specific HR, and probability of changing NYHA class, derived from Val-HeFT. The model is informed with NYHA state-and age-specific utilities and hospitalization probabilities (adjusted for gender and ACEi-use). Costs are calculated in the perspective of the Italian NHS and account for drugs and CHF hospitalizations. The cohort was defined to represent Italian patients with mild-to-severe CHF and LFEV < 40% over 45 years (Val-HeFT inclusion criteria). Results were calculated through 30,000 iterations of the patient-level simulation (each individual is created by drawing from age, gender and ACE-I use distributions of the cohort). Annual discount rate of 3.5% was applied to costs and health outcomes. Uncertainty around model parameters was handled by probabilistic sensitivity analysis (PSA), performed by simultaneous drawing of each model parameter from the original data source 95% CI, or from the +/-10% range where original CI was unavailable. RESULTS: On average, in the simulation timeframe patients live 4.4 years (3.2 QALYs), with a slight increase in the valsartan group, in which costs are reduced by approximately €500/pt. In subgroup
